Pfizer (PFE) Announces Positive Phase 2b Results for Obesity Drug Showing 12.30% Weight Loss

Core Insights - Pfizer Inc. has announced positive topline results from its Phase 2b VESPER-3 study of PF-08653944, an injectable GLP-1 receptor agonist, achieving a statistically significant weight loss of up to 12.3% at 28 weeks [1][6] - The study confirmed a favorable safety and tolerability profile, with gastrointestinal side effects primarily being mild to moderate, reinforcing Pfizer's confidence in pursuing higher maintenance doses in future trials [2] - Following the acquisition of Metsera, Pfizer is accelerating its obesity development program, planning over 20 studies and advancing 10 Phase 3 trials for PF-08653944 by 2026 [3] Company Overview - Pfizer Inc. is engaged in the discovery, development, manufacturing, marketing, distribution, and sale of biopharmaceutical products both in the US and internationally [4]